The impact of vaccination and patient characteristics on influenza vaccination uptake of elderly people: A discrete choice experiment by Bekker-Grob, E.W. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/188598
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
The impact of vaccination and patient characteristics on influenza
vaccination uptake of elderly people: A discrete choice experiment
Esther W. de Bekker-Grob a,b,⇑, Jorien Veldwijk a,c, Marcel Jonker a, Bas Donkers d, Jan Huisman e,
Sylvia Buis f, Joffre Swait g, Emily Lancsar h, Cilia L.M. Witteman i, Gouke Bonsel j, Patrick Bindels k
a Section of Health Technology Assessment & Erasmus Choice Modelling Centre, Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands
b Section of Medical Decision Making & Erasmus Choice Modelling Centre, Department of Public Health, Erasmus MC – University Medical Centre, Rotterdam, The Netherlands
cCentre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden
dDepartment of Business Economics & Erasmus Choice Modelling Centre, Erasmus School of Economics, Erasmus University, Rotterdam, The Netherlands
eGeneral Practice, Het Doktershuis, Ridderkerk, The Netherlands
fGeneral Practice, Gezondheidscentrum Ommoord, Rotterdam, The Netherlands
g Institute for Choice, University of South Australia, Sydney, Australia
hCentre for Health Economics, Monash University, Melbourne, Australia
iBehavioural Science Institute, Radboud University, Nijmegen, The Netherlands
jEuroQoL Foundation, Rotterdam, The Netherlands
kDepartment of General Practice, Erasmus MC – University Medical Centre, Rotterdam, The Netherlands
a r t i c l e i n f o
Article history:
Received 15 November 2017
Received in revised form 17 January 2018
Accepted 19 January 2018
Available online 6 February 2018
Keywords:
Influenza vaccination
Vaccination characteristics
Patient characteristics
Discrete choice experiment
Vaccination uptake
a b s t r a c t
Objectives: To improve information for patients and to facilitate a vaccination coverage that is in line with
the EU and World Health Organization goals, we aimed to quantify how vaccination and patient charac-
teristics impact on influenza vaccination uptake of elderly people.
Methods: An online discrete choice experiment (DCE) was conducted among 1261 representatives of the
Dutch general population aged 60 years or older. In the DCE, we used influenza vaccination scenarios
based on five vaccination characteristics: effectiveness, risk of severe side effects, risk of mild side effects,
protection duration, and absorption time. A heteroscedastic multinomial logit model was used, taking
scale and preference heterogeneity (based on 19 patient characteristics) into account.
Results: Vaccination and patient characteristics both contributed to explain influenza vaccination uptake.
Assuming a base case respondent and a realistic vaccination scenario, the predicted uptake was 58%. One-
way changes in vaccination characteristics and patient characteristics changed this uptake from 46% up
to 61% and from 37% up to 95%, respectively. The strongest impact on vaccination uptake was whether
the patient had been vaccinated last year, whether s/he had experienced vaccination side effects, and
the patient’s general attitude towards vaccination.
Conclusions: Although vaccination characteristics proved to influence influenza vaccination uptake, cer-
tain patient characteristics had an even higher impact on influenza vaccination uptake. Policy makers and
general practitioners can use these insights to improve their communication plans and information
regarding influenza vaccination for individuals aged 60 years or older. For instance, physicians should
focus more on patients who had experienced side effects due to vaccination in the past, and policy mak-
ers should tailor the standard information folder to patients who had been vaccinated last year and to
patient who had not.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Influenza is a major cause of illness and death [1]. Every year in
the United States, influenza infections are associated with approx-
imately 55,000 of deaths, the majority occurring from seasonal
influenza among adults aged 65 years or older [2,3]. The same phe-
nomenon is seen in Europe with a lower-bound estimated rate of
excess deaths of 40,000 cases per season [4].
Influenza vaccination is promoted by many health authorities,
as the single option of influenza prevention [5]. However, despite
general consensus and recommendations that annual influenza
vaccination should be given to all individuals with age 60 years
https://doi.org/10.1016/j.vaccine.2018.01.054
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or older [5,6], many countries in Europe do not achieve high cover-
age in these groups [7]. In several countries, there is even a lower-
ing trend of the influenza vaccination rate for elderly people [8,9].
To satisfy vaccination coverage recommendations in line with the
EU and World Health Organization goals, more efforts are needed
and more effective strategies have to be developed to increase
influenza vaccination coverage [10].
A first important step towards better strategies is to obtain
insights into how vaccination characteristics (the ‘offer’) and
patient characteristics (the ‘recipient’) impact influenza vaccina-
tion uptake, assuming uptake is not random. These insights will
be useful for i) general practitioners informing their patients
(e.g., using more tailored type of invitation letter); and ii) policy
makers to tailor their general brochures (e.g., focusing more on
the facilitators or barriers regarding influenza vaccination uptake).
However, there are no quantitative studies investigating how vac-
cination and patient characteristics impact on influenza vaccina-
tion uptake.
It is precisely this information that is needed to develop
effective strategies to increase influenza vaccination uptake.
Therefore, the aim of this study is to quantify how vaccination
and patient characteristics impact on influenza vaccination
uptake of elderly people. Towards this end we used a discrete
choice experiment (DCE), a quantitative approach that is increas-
ingly used in healthcare research to obtain quantitative informa-
tion on the relative merits of complex outcomes. DCE combines
an empirical task (respondents have to select one out of two
stylized outcomes reflecting the decision at hand), with post
hoc computations on the resulting data from a large set of
respondents [11–13].
2. Methods
2.1. Discrete choice experiment
A DCE assumes that the overall preference for a multi-facetted
medical intervention, such as an influenza vaccination, can be
approached by first decomposing the intervention consequences
into separate characteristics (technically called ’attributes’; e.g.
vaccination effectiveness, risk of side effects, out-of-pocket costs)
[14]. Those characteristics are further specified by variants of that
characteristic (so-called attribute ’levels’, such as for vaccination
effectiveness 20%, 40%, 60%, 80% chance that the vaccinated person
is protected against influenza symptoms).
The next step rests on the assumption that the individual’s pref-
erence for a medical intervention (including rejection) is deter-
mined by the levels of those attributes [14]. The relative
importance of attributes, and, within the attribute, the importance
of the levels, can be empirically determined. In DCE, respondents
are forced to make trade-offs by offering a series of choices
between two (or more) medical intervention profiles [15] (see
Fig. 1 for an example of such a so-called ‘choice task’). Specific
computational schemes enable the investigator to derive numbers
for the relative preference for attribute levels [16].
2.2. Attributes and levels
We used a literature search [17–21], interviews with experts in
the field of influenza vaccination (n = 4) and three focus groupswith
patients aged 60 years and older from general practices (n = 21; i.e.,
the target group) to develop and operationalize influenza vaccina-
1. Effectiveness
Flu-vaccination 1 Flu-vaccination 2 No flu-vaccination
60% 40% 0%
2. Serious side-effects 100 out of every 
1.000.000
1 out of every 
1.000.000
3. Mild side-effects 3 out of every 10 3 out of every 10
4. Protection duration 3 months 3 months
5. Absorption time 4 weeks 2 weeks
I choose for:
n.a.
Fig. 1. Example choice set.
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tion attributes with their levels. Noteworthy, in the Netherlands,
recipients of 60 years and older (our target population) do not have
to pay for influenza vaccination. After the qualitative work, the
nominal group technique was applied, which allowed us to make
a selection of influenza vaccination attributes [22]: vaccination
effectiveness, risk of severe side effects, risk ofmild side effects, pro-
tection duration, and absorption time (Table 1). The levels for each
attribute incorporated the range of possible vaccination outcomes
based on current literature and near future/plausible expectations
(Table 1). To define vaccination effectiveness of –for example–
60%we used this description: ‘‘from all 100 personswhowould nor-
mally get flu, due to vaccination 60 out of these 100 persons would
not get flu anymore, while 40 persons would still get flu”.
2.3. DCE design
The combination of, in our case, five attributes with two, three
(three times) and four levels each results in 216 (21  33  41)
potential influenza vaccination alternatives, and in 23,220 (216
 215 ½) different or unique comparisons of influenza vaccina-
tion scenarios (i.e., choice tasks). Choice tasks consisted of two
influenza vaccination alternatives and a ‘no vaccination’ option
was added to allow respondents to ‘opt out’ (Fig. 1). The ‘opt out’
alternative was necessary as influenza vaccination is a preventive
intervention and, as in real life, respondents are not obliged to
get vaccinated against influenza. Respondents were asked to con-
sider all three alternatives in a choice task as realistic alternatives
and to choose the alternative that appealed most to them.
Since it is not feasible to present a single individual with 23,220
choice tasks, selection procedures have been developed which cre-
ate a much smaller subset of choice tasks with little loss of infor-
mation or precision; these subsets are called ’designs’. So-called
’Bayesian efficient design algorithms’ are designs which minimize
the effort (respondent burden) to arrive at reliable parameters,
i.e. the group’s preference weights assigned to the attribute levels.
Such algorithms maximise the D-efficiency criterion [23]; here we
used Fortran programming language for computations. To maxi-
mize the D-efficiency of the DCE design while accommodating sub-
stantial respondent heterogeneity, a DCE design format commonly
referred to as a heterogeneous DCE design [24] was used. That is,
we used a heterogeneous DCE design consisting of 10 sub-
designs. Each respondent was offered one sub-design containing
16 choice tasks. Together these sub-designs were optimal to esti-
mate a so-called standard multinomial logit model, based on a
main-effects utility function with several 2-way interactions (i.e.,
interaction between the attribute vaccination effectiveness and
other attributes). The sub-designs deliberately restricted the num-
ber of different levels of attributes in each choice task to 3 (instead
of 5), to avoid cognitive overload. The prior preference information
(attribute weights) as required for the Bayesian efficient optimiza-
tion approach was obtained from best guess priors, and updated
after a pilot run of 300 respondents. As final result the develop-
mental phase ended with 10 versions of questionnaires, each con-
taining 16 different choice tasks, each choice task consisting of two
different vaccination options and the no vaccination option. Pilot
testing had provided the required prior preference information to
run the computations after data collection.
2.4. Questionnaire
Apart from the 16 choice tasks described above, the question-
naire further contained questions on 19 patient characteristics.
There were 8 background variables (age, gender, educational level,
nationality, having any disease, GP visit last month, hospital visit
last month, and heath condition); 8 influenza vaccination related
variables (general attitude towards influenza vaccination, vacci-
nated last year, intention to opt for next influenza vaccination,
experienced side effects, experienced flu although being vacci-
nated, experienced flu symptoms last year, religious or belief
exemption for influenza vaccination, and impact of health condi-
tion on family); and 3 decision-making skills variables (decision
style, health literacy, and numeracy). These 19 patient characteris-
tics were of interest based on literature, expert opinions and focus
groups (see Section 2.2), as they all are hypothesized to have an
impact on vaccination uptake. The questionnaire also contained
questions assessing experienced difficulty of the questionnaire
(5-point scale) and the length of the questionnaire (3-point scale).
The questionnaire itself was structured as follows. First, the sur-
vey was briefly introduced, followed by the 8 background variable
questions. Then the attributes and levels of influenza vaccination
and the DCE choice tasks were explained. Subsequently, one
warm-up question was included that carefully explained the lay-
out and the required trade-offs of the DCE choice task questions.
Then, the set of 16 pairwise choice tasks was shown. To promote
respondent engagement with the DCE, halfway through the choice
tasks (between tasks 8 and 9), 8 influenza vaccination-related vari-
able questions were given. The pre-pilot study did not show signs
of fatigue, and the break between choice sets 1–8 and 9–16 was
positively debriefed. Finally, at the end of the survey, the respon-
dents were asked validated Likert scale questions related to their
decision style [25], health literacy [26,27], and numeracy [28,29],
and questions about complexity and length of the questionnaire.
We conducted a pre-pilot study with debriefing (n = 20; the
patients used for this pre-pilot study were another 20 to the focus
groups (i.e. no overlap)) to verify feasibility. On the one hand, it
was a qualitative pre-pilot by using a think-aloud strategy to test
whether patients understood the questionnaire and interpreted
the attributes and levels in a way we wanted them to. On the other
hand, it was also a quantitative pre-pilot as the DCE outcomes were
used as prior information for the pilot DCE study design. The data
of these patients were not included in the final analyses.
2.5. Study sample
An online sample of 1419 individuals aged 60 years and older
from the Dutch general population, nationally representative in
terms of age, gender, education, and geographic region was
recruited via Survey Sampling International, a commercial survey
sample provider. Calculation of optimal sample sizes for a DCE is
complicated as it depends on the true values of the unknown
parameters estimated in the discrete choice models [30]. However,
based on our DCE design and pilot run, and using the sample size
calculation of De Bekker-Grob et al. [31], a sample size of 1200
respondents was large enough to be able to find differences
between attribute levels. Respondents were randomly assigned
to 1 of the 10 questionnaire versions. Hence, each questionnaire
agreed to 1 of the 10 DCE sub-designs created (noteworthy, each
sub-design itself was given in a different order to the respondent,
so that many different choice set versions were available). Respon-
dents received a small financial compensation (€2,20) for complet-
ing the survey. Approval for the study was obtained from the
Medical Ethics Committee, Erasmus MC (MEC-2016-095).
Table 1
Vaccination attributes and levels.
Vaccination attributes Levels
Effectiveness (%) 20–40–60–80
Risk of severe side effects ( out of 1,000,000) 1–10–100
Risk of mild side effects ( out of 10) 1–3–5
Protection duration (months) 3–6–12
Vaccine will become active ( weeks after vaccination) 2–4
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2.6. Statistical analyses
Several models exist to analyse discrete choice data [12,32,33].
Each choice model has its set of features, which should fit best to
the intentions of the research. The aim of our study was to quantify
how vaccination and patient characteristics impact on influenza
vaccination uptake so that information for patients and uptake
can be improved. Therefore, we were especially interested in relax-
ing the preference homogeneity and/or IID assumption. That is,
observed differences in estimated preference parameters in dis-
crete choice models can be due to preference and/or choice incon-
sistency. Considering choice consistency (i.e. scale effects or scale
heterogeneity) may account for a significant amount of the
observed variation in the results of the DCE when comparing pref-
erences across subgroups (e.g. persons aged 60–69 years old might
have a higher choice consistency than persons aged 70 years and
older (scale heterogeneity), while their preferences might be sim-
ilar (preference homogeneity)). Given our interest in accounting
for systematic preference heterogeneity (i.e., to determine whether
vaccination uptake depends on specific patient characteristics),
while also taking scale effects and our sample size into account,
led to the decision to employ a random intercept MNL model with
error term heteroscedasticity (or scale variation) to analyse the
choice observations. A (random) treatment preference (in DCE lan-
guage also called a random alternative specific constant (i.e., ran-
dom intercept)) is the difference in the mean of the preference
(utility) for the no flu vaccination alternative compared to the flu
vaccination alternative, if all attributes are set to zero. Using
Pythonbiogeme Software and taking the best model fit into
account based on the Bayesian Information Criterium (BIC), the
observations were analysed by a heteroscedastic model in error
component. We used a four-step approach to determine the opti-
mal utility function. First, we tested a number of different specifi-
cations for the utility function (i.e. categorical or numerical
attribute levels, two-way interactions between attributes, several
attribute transformations) (model 1; MNL model). Second, we
added and tested a number of different scale components to the
utility function (model 2; HMNL model). Third, we allowed for sev-
eral covariates (19 patient characteristics) to enter as interactions
into the utility function (model 3; HMNL model plus systematic
preference heterogeneity). Finally, a random intercept was added
to the utility function to define the best utility function (model
4; same model as model 3, but taking the IIA assumption into
account as well by using a random intercept). The random inter-
cept takes into account whether respondents systematically
viewed the flu vaccination(s) differently from the no flu vaccina-
tion alternative. The random intercept model is a simple form of
mixed logit model, in which only the ASC is assumed to be dis-
tributed across the population. This specification essentially cre-
ates two nests (one for the vaccination alternative(s), another for
the no-flu alternative), thus mimicking a nested logit specification.
For the coefficients, the statistical significance (p-value  0.05)
indicates that respondents considered the attribute important in
making their choices in the DCE. The sign of the coefficient reflects
whether the attribute has a positive or negative effect on utility. In
terms of the scale parameters, statistically significant parameter
estimates indicate that the associated covariate captures more
(positive parameter) or less (negative parameter) consistent
choices.
2.7. Expected uptake of flu vaccination
Choice probabilities (mean uptakes) were calculated to provide
a way to convey DCE results to general practitioners and policy
makers that are more easily understood. We calculated the choice
probability for a base case vaccination and a base case patient by
taking the exponent of the total utility for vaccination divided by
the exponent of utility of both vaccination and no vaccination.
Noteworthy, in the calculation of the mean uptake we took all
heterogeneity into account as the mean uptake is not just equal
to the uptake of someone with average coefficient values. The
base-case vaccination program was chosen to resemble a common
practice situation, and included the following attribute levels: vac-
cine effectiveness of 60%, 1 out of 1,000,000 risk of severe side
effects, 30% risk of mild side effects, protection duration of 6
months, and absorption time of 2 weeks. As there was no clear
rationale to choose a specific base case patient, we decided to
opt for a base case patient that had all dummy-coded ‘1’ character-
istics: male, good numeracy, good health literacy, aged >65 years,
no flu symptoms last year, no GP visit last month, not having a dis-
ease, positive vaccination attitude, deliberative decision style,
higher educated, no impact health condition family, good health,
no flu vaccination last year, no vaccination side effects, and no
flu after being vaccinated. To investigate the impact of changing
a vaccination characteristic or a patient characteristic on vaccina-
tion uptake, univariate estimates (i.e. one-way impact) for pre-
dicted probability of vaccination uptake were calculated.
3. Results
3.1. Respondents
From the total of 1419 panel members aged 60 years and older
who started the survey, 1261 (88.9%) completed the questionnaire,
resulting in 158 dropouts (11.1%) (Table 2). Less than 3% of respon-
dents that completed the survey had difficulty filling in the ques-
tionnaire, and 1043 respondents (82.7%) judged the length of the
questionnaire as fine. Respondents had a mean age of 66.1 years
(SD = 5.1), 712 respondents (56.6%) were male, and one third had
a lower educational level (Table 3). About 75% of the respondents
reported that they were in good health, 336 respondents (26.6%)
had experienced influenza (symptoms) last year, and 387 respon-
dents (30.7%) mentioned that they had never been vaccinated
against influenza (Table 2). Sixty-four percent (64%) of the respon-
dents stated that they would opt for flu vaccination if they would
receive an invitation this year.
Table 2
Descriptives.
N %
Responsiveness
Completes 1261
Dropouts 158 11.1
Time between starting and ending DCE part of the questionnaire
Median (sec) 641
3–5 min 50 4.0
5–10 min 482 38.2
10–15 min 465 36.9
15–20 min 153 12.1
20–25 min 57 4.5
>25 min 54 4.3
Difficulty filling the questionnaire (yes)
Very easy 270 21.4
Easy 638 50.6
Neutral 318 25.2
Difficult 32 2.5
Very difficult 3 0.2
Length of the questionnaire (good)
Too long 218 17.3
Not too long, not too short 1043 82.7
Too short 0 0
1470 E.W. de Bekker-Grob et al. / Vaccine 36 (2018) 1467–1476
3.2. DCE results
The heteroscedastic multinomial logit model, that included
patient characteristics as well as a random intercept, resulted in
the best model fit (see column HMNL++, Tables 4 and 5). As a valid-
ity check, the predicted vaccination uptake of 62.3% (CI 59.6%–
65.0%) at an aggregate level was in line with the observed vaccina-
tion uptake of 64% (i.e., what respondents stated they will do; see
previous paragraph) (Table 5). That is, the observed flu vaccination
uptake on the group level was correctly predicted by our DCE (see
Table 4, column HMNL++, which we used as our final analysis). As a
check for response fatigue, the consistency in responses to choice
set 9–16 did not differ significantly from the consistency in
responses to choice set 1–8 (p = 0.24).
Table 5 presents the DCE results in detail. In general, all attri-
butes proved to be important (p < .01), except for absorption time
(p = .25). The attribute levels had the expected sign and order
(Table 5) and showed, therefore, theoretical validity. In other
words, there was a higher probability to opt for vaccination, if
the vaccine was more effective, had a smaller risk of serious and
mild side effects, and had a longer protection duration.
The estimated standard deviation of the alternative specific
constant (i.e. random intercept) was strongly significant (p < .001
), which indicated preference heterogeneity among respondents
for the option ‘no vaccination’ (Table 5). The significant two-way
interaction between the attribute ‘vaccination effectiveness’ and
attribute level ‘a 10 out of 1,000,000 risk of serious side effects’
showed that the total positive value of ‘vaccination effectiveness’
was tempered if there was ‘a 10 out of 1,000,000 risk of serious side
effects’ compared to ‘a 1 out of 1,000,000 risk of serious side
effects’.
Our findings detected scale heterogeneity. That is, the consis-
tency of the choices depended on the numeracy skills and gender
of respondents, and whether respondents had experienced flu
symptoms last year: the choices to opt-in or opt-out for flu vacci-
nation were more consistent if the respondent had good numeracy
skills, was female, and/or did not experience flu symptoms last
year (Table 5).
Preference heterogeneity among respondents from systematic
sources was found to be substantial. Fifteen out of 19 patient char-
acteristics had an impact on one or more attribute levels, and
hence directly on the predicted vaccination uptake (see next
paragraph).
3.3. Expected uptake of flu vaccination
Assuming a common practice influenza vaccination (i.e., vaccine
effectiveness of 60%, 1 out of 1,000,000 risk of severe side effects,
30% risk of mild side effects, protection duration of 6 months,
and absorption time of 2 weeks) and a base case patient, the utili-
ties were 8.8 and 7.2 for the vaccination and ‘no vaccination’ option
respectively. That is, the predicted influenza vaccination uptake
was 58% (Figs. 2a and 2b). One-way changes in vaccination charac-
teristics changed this uptake from 46% to 61% (Fig. 2a). Note espe-
cially that the vaccination uptake decreases substantially (from
58% to 46% and from 58% to 51%, respectively) if the vaccination
effectiveness decreases from 60% to 20%, or if the risk of severe side
effects increases from 1 out of 1,000,000 to 100 out of 1,000,000.
Table 3
Respondents’ characteristics.
Respondents
N = 1261 (%)
Male 712 56.5
Age (mean; sd) 66.1 5.1
Aged 60–65 years 583 46.2
Aged 65 years or older 678 53.8
Education
Low 424 33.6
Medium 434 34.4
High 399 31.6
Nationality Dutch 1241 98.4
Health
Good 945 74.9
Moderate 277 22.0
Bad 39 3.1
Visited GP last month (yes) 409 32.4
Visited Hospital last month (yes) 294 23.3
Suffering from the following disease:
Lung 199 15.8
Heart 163 12.9
Diabetes 194 15.4
Kidney 24 1.9
Low resistance 28 2.2
None 789 62.6
Influenza (symptoms) last year (yes) 336 26.6
Impact of certain conviction on flu
vaccination (yes)
49 3.9
Vaccinated against influenza
Yes, last year 643 51.0
Yes, 2 years or longer ago 228 18.1
No 387 30.7
Vaccination experience effectiveness
(good)
646 51.2
Vaccination experience side effects
None 670 53.1
Mild 157 12.5
Severe 47 3.7
Family impacts influenza decision (yes) 70 5.6
Say that s/he will opt for vaccination
(fixed choice; yes)
807 64.0
General attitude vaccination
In favour 549 43.5
Neutral 394 31.2
Against 318 25.2
Health literacy
Average (mean; sd) 2.9 0.5
Good health literacy (scored 3 or higher) 563 44.6
Numeracy
SNS average (mean; sd) 4.1 1.1
Objective scores correct (yes) 852 67.6
Good numeracy (i.e. 4 or higher SNS +
obj scores correct (yes))
628 49.8
Decision style
Decision style average (mean; sd) 2.8 0.5
Rather deliberative (3<) 219 17.4
Neutral (3) 303 24.0
Rather intuitive (<3) 739 58.6
Table 4
DCE model fit results based on 1261 respondents.
MNL HMNL HMNL+ HMNL++
Predicted vaccination
uptake: mean
62.3% 60.4% 63.3% 62.3%
(95% CI) (59.6–
65.0%)
(57.7–
63.1%)
(60.6–
65.9%)
(59.6–
65.0%)
LogLikelihood 17,228 17,177 13,539 11,506
Degrees of freedom 12 20 76 77
AIC 1.709 1.705 1.350 1.148
BIC 1.712 1.710 1.369 1.168
Respondents (n) 1261
Observed vaccination
uptake
64.0%
Note: MNL = multinomial model; HMNL = heteroscedastic model; HMNL+ =
heteroscedastic model plus systematic preference heterogeneity; HMNL++ =
Heteroscedastic model plus systematic preference heterogeneity plus random
intercept; AIC = Akaike Information Criterion; BIC = Baysian Information Criterion.
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Table 5
DCE results.
MNL model HMNL model HMNL model + systematic
preference heterogeneity
HMNL model + systematic
preference heterogeneity +
random intercept
Utility function 95% CI 95% CI 95% CI 95% CI
coeff Lower Upper coeff Lower Upper coeff Lower Upper coeff Lower Upper
Alternative-specific constant
No vaccination 2.50 2.30 2.70 2.58 2.17 2.99 2.09 1.40 2.78 6.65 4.36 8.94
95% CI 95% CI 95% CI 95% CI
OR Lower Upper OR Lower Upper OR Lower Upper OR Lower Upper
Attributes (main effects)
Effectiveness (log) 1.93 1.83 2.03 1.92 1.73 2.13 0.99 0.83 1.18 1.29 1.05 1.59
Serious side effects
1/1.000.000 (ref) 1.65 1.71 1.29 1.24
10/1.000.000 1.80 1.49 2.18 1.78 1.46 2.16 1.68 1.33 2.12 1.60 1.26 2.04
100/1.000.000 0.34 0.27 0.42 0.33 0.25 0.43 0.46 0.35 0.60 0.50 0.38 0.66
Mild side effects (per 10%) 0.94 0.93 0.95 0.58 0.57 0.58 0.90 0.88 0.92 0.86 0.84 0.89
Protection duration
3 mo (ref) 0.60 0.63 0.72 0.65
6 mo 1.31 1.08 1.58 1.29 1.08 1.55 1.16 0.93 1.45 1.11 0.88 1.40
12 mo 1.28 1.05 1.57 1.23 1.01 1.49 1.20 0.94 1.54 1.39 1.08 1.79
Waiting time
2 wks (ref) 0.98 0.98 0.99 1.03
4 wks 1.02 1.00 1.04 1.02 1.00 1.04 1.02 0.97 1.06 0.97 0.93 1.02
Two-way interactions
Log_eff x serious10 0.86 0.82 0.91 0.87 0.82 0.91 0.88 0.83 0.93 0.90 0.84 0.95
Log_eff x serious100 1.16 1.10 1.23 1.18 1.12 1.24 1.04 0.98 1.12 0.96 0.89 1.02
Log_eff x dur6 0.95 0.90 1.00 0.95 0.90 1.00 0.97 0.92 1.03 0.99 0.93 1.05
Log_eff x dur12 1.01 0.96 1.07 1.01 0.96 1.08 1.02 0.96 1.08 1.01 0.95 1.08
coeff 95% CI coeff 95% CI coeff 95% CI coeff 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
Scale heterogeneity
Good nummeracy – – – 0.42 0.31 0.54 0.20 0.13 0.27 0.29 0.15 0.43
Deliberative DM style – – – 0.22 0.10 0.34 0.26 0.35 0.17 0.01 0.14 0.15
good health literacy – – – 0.10 0.20 0.01 0.02 0.08 0.05 0.03 0.13 0.07
Age >65 years – – – 0.11 0.22 0.00 0.09 0.15 0.02 0.03 0.12 0.06
Flu symptoms last year – – – 0.16 0.29 0.03 0.13 0.20 0.06 0.15 0.25 0.05
gp visit last month – – – 0.12 0.24 0.01 0.05 0.11 0.02 0.06 0.15 0.04
Male – – – 0.28 0.39 0.17 0.03 0.09 0.04 0.15 0.24 0.05
No disease – – – 0.15 0.02 0.27 0.03 0.10 0.03 0.04 0.14 0.06
95% CI 95% CI 95% CI 95% CI
OR Lower Upper OR Lower Upper OR Lower Upper OR Lower Upper
Systematic preference heterogeneity
Age >65 yr  eff – – – – – – 0.92 0.89 0.96 0.86 0.79 0.92
Age >65 yr  dur6 – – – – – – 1.00 0.93 1.07 0.99 0.87 1.12
Age >65 yr  dur12 – – – – – – 0.93 0.87 1.00 1.31 1.22 1.40
Attitude for  eff – – – – – – 2.08 1.92 2.25 2.02 1.69 2.41
Attitude for  serious10 – – – – – – 1.03 0.95 1.12 1.03 0.95 1.12
Attitude for  serious100 – – – – – – 0.84 0.76 0.94 0.91 0.81 1.02
Attitude for  dur6 – – – – – – 0.98 0.90 1.07 0.98 0.90 1.07
Attitude for  dur12 – – – – – – 1.36 1.24 1.50 1.31 1.18 1.45
Attitude for wait4 – – – – – – 0.94 0.88 1.00 0.95 0.89 1.01
No disease  constant ’no vacc’ – – – – – – 0.59 0.50 0.70 0.57 0.14 2.39
No disease  serious10 – – – – – – 1.00 0.93 1.07 0.99 0.92 1.06
No disease  serious100 – – – – – – 0.89 0.82 0.98 0.88 0.80 0.97
Deliberative DM style  constant ’no vacc’ – – – – – – 24.53 9.43 63.85 5.10 0.78 33.57
Deliberative DM style  eff – – – – – – 2.37 1.87 3.00 1.89 1.46 2.44
Deliberative DM style  serious10 – – – – – – 1.04 0.94 1.16 1.02 0.93 1.11
Deliberative DM style  serious100 – – – – – – 0.79 0.68 0.91 0.89 0.77 1.03
Deliberative DM style wait4 – – – – – – 1.11 1.02 1.19 1.06 0.99 1.13
High education  constant ’no vacc’ – – – – – – 2.25 1.30 3.90 2.16 0.48 9.78
High education  eff – – – – – – 1.31 1.14 1.50 1.33 1.14 1.54
High education  serious10 – – – – – – 1.04 0.96 1.12 1.03 0.96 1.11
High education  serious100 – – – – – – 0.88 0.80 0.96 0.89 0.81 0.99
Impact family  eff – – – – – – 1.14 1.05 1.22 1.49 1.15 1.94
Impact family wait4 – – – – – – 0.88 0.79 0.97 0.87 0.78 0.97
Flu symptoms last year  constant ’no vacc’ – – – – – – 2.01 1.12 3.60 0.93 0.19 4.46
Flu symptoms last year  eff – – – – – – 1.19 1.03 1.37 1.23 1.03 1.47
Last month GP visit  dur6 – – – – – – 1.03 0.95 1.11 1.02 0.94 1.10
Last month GP visit  dur12 – – – – – – 1.09 1.00 1.18 1.10 1.01 1.19
Good health  ascn – – – – – – 4.39 2.49 7.76 26.58 4.50 156.92
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One-way changes in patient characteristics have an even larger
impact on the predicted vaccination uptake. Assuming a common
practice influenza vaccination and the base case respondent men-
tioned above (that led to a predicted vaccination uptake of 58%),
one-way changes of patient characteristics changed this uptake
substantially from 37% to 95% (Fig. 2b). The strongest impact on
vaccination uptake was due to whether the patient had been vac-
cinated last year, whether s/he had experienced vaccination side
effects, and the patient’s general attitude towards vaccination,
respectively.
4. Discussion
This study showed that vaccination and patient characteristics
both significantly influence influenza vaccination uptake. Assum-
ing a base case respondent and a common practice vaccination sce-
nario, the predicted influenza vaccination uptake was 58%. One-
way changes in vaccination characteristics changed this uptake
from 46% to 61%, whereas one-way changes of patient characteris-
tics changed this uptake from 37% to 95%. The strongest impact on
vaccination uptake was whether the patient had been vaccinated
last year, whether s/he had experienced vaccination side effects,
and the patient’s general attitude towards vaccination,
respectively.
There are no previous DCE studies investigating how vaccina-
tion and patient characteristics impact on influenza vaccination
uptake. However, DCE studies that investigated individuals’ prefer-
ences for HPV vaccination or rotavirus vaccination found that vac-
cination effectiveness, protection duration, and/or risk of side-
effects influence individuals’ preferences for vaccination [34,35],
which is in line with our findings. Our finding that the experienced
vaccination side effects had an important influence on vaccination
uptake was also found by a DCE study who focused on the effect of
perceived risks on the demand for vaccination [18]. Our finding
that if a patient was not in good health, or had a family member
with such a condition, s/he had a higher probability to opt for influ-
enza vaccination is an encouraging one. This is exactly the category
of patients that benefits most of influenza vaccination.
Our study showed that if the patient had in general a nega-
tive attitude towards vaccination and/or if the patient had not
opted for an influenza vaccination last year, both had a signifi-
cant negative impact on the vaccination uptake. The use of this
information by GPs (in The Netherlands, the GP invites the
patients for influenza vaccination) and policy makers can
increase uptake; for example by taking the opportunity to
inform such patients aged 60 years and older directly regarding
influenza vaccination, when s/he visits the GP several weeks
before the seasonal influenza vaccination. That is, to clarify that
Table 5 (continued)
MNL model HMNL model HMNL model + systematic
preference heterogeneity
HMNL model + systematic
preference heterogeneity +
random intercept
Utility function 95% CI 95% CI 95% CI 95% CI
coeff Lower Upper coeff Lower Upper coeff Lower Upper coeff Lower Upper
Good health  eff – – – – – – 1.28 1.11 1.47 1.31 1.12 1.52
Good health literacy  Constant ’no vacc’ – – – – – – 0.48 0.29 0.79 0.36 0.09 1.39
Good health literacy  eff – – – – – – 0.83 0.73 0.94 0.84 0.73 0.96
Good health literacy mild – – – – – – 1.04 1.01 1.07 1.04 1.01 1.07
Good health literacy  serious10 – – – – – – 1.02 0.95 1.09 1.02 0.95 1.09
Good health literacy  serious100 – – – – – – 1.11 1.01 1.21 1.09 0.99 1.21
Good nummeracy  constant ’no vacc’ – – – – – – 5.47 3.02 9.93 7.24 1.51 34.68
Good nummeracy  eff – – – – – – 1.47 1.36 1.58 1.47 1.20 1.81
Good nummeracy  serious10 – – – – – – 0.99 0.86 1.14 1.00 0.93 1.07
Good nummeracy  serious100 – – – – – – 0.90 0.84 0.96 0.93 0.81 1.07
Good numeracy  dur6 – – – – – – 1.05 0.98 1.13 1.05 0.98 1.13
Good nummeracy  dur12 – – – – – – 0.86 0.77 0.95 0.82 0.75 0.90
Male  constant ’no vacc’ – – – – – – 0.61 0.52 0.71 0.19 0.05 0.71
Male  serious10 – – – – – – 0.98 0.91 1.05 0.97 0.91 1.04
Male  serious100 – – – – – – 1.21 1.11 1.32 0.86 0.78 0.94
Vacc last year  constant ’no vacc’ – – – – – – 0.12 0.07 0.20 <0.01 <0.01 <0.01
Vacc last year  eff – – – – – – 1.02 0.89 1.16 0.95 0.81 1.13
Vacc last year  serious10 – – – – – – 1.05 0.96 1.14 1.04 0.95 1.14
Vacc last year  serious100 – – – – – – 0.83 0.74 0.94 0.96 0.84 1.09
Vacc last year mild – – – – – – 0.97 0.94 1.00 1.00 0.97 1.04
Vacc last year  dur6 – – – – – – 1.02 0.93 1.10 1.00 0.91 1.09
Vacc last year  dur12 – – – – – – 1.30 1.18 1.43 1.24 1.12 1.38
Vacc last year wait4 – – – – – – 0.92 0.86 0.98 0.93 0.87 1.00
Flu although being vacc  eff – – – – – – 0.92 0.87 0.97 0.87 0.73 1.03
No side effects  constant ’no vacc’ – – – – – – 0.35 0.29 0.41 0.02 <0.01 0.08
No side effects  serious10 – – – – – – 0.97 0.90 1.05 0.97 0.89 1.05
No side effects  serious100 – – – – – – 1.11 1.01 1.23 1.13 1.02 1.26
No side effects wait4 – – – – – – 1.06 1.00 1.12 1.07 1.00 1.13
95% CI 95% CI 95% CI 95% CI
SD Lower Upper SD Lower Upper SD Lower Upper SD Lower Upper
Random intercept
– – – – – – – – – 7.69 6.20 9.18
Goodnessoffit
LL 17,228 17,177 13,539 11,506
Number Free Param. 12 20 76 77
AIC 1.709 1.705 1.350 1.148
BIC 1.712 1.710 1.369 1.168
Respondents 1261 1261 1261 1261
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a patient will not get influenza because of the vaccination as it
contains a dead virus, or to explain that several symptoms
reported after influenza vaccination are not always the result
of the vaccination. Further research is warranted to ascertain
whether the GP’s or other healthcare professionals’ beliefs about
influenza vaccination will moderate the positive impact of such a
strategy on influenza vaccination uptake. Another strategy that
begs further research is to investigate whether sending a more
tailored letter to non-attenders of influenza vaccination last year
might have a positive impact on vaccination uptake.
The current study has several strengths. First, we used qualita-
tive techniques (interviews, focus groups, and nominal group tech-
niques) to obtain insights into influenza vaccination attributes to
inform the design of the DCE. Using qualitative methods to inform
a DCE is important to ascertain that relevant attributes are
included in the choice task [13]. Second, a state-of-the-art hetero-
geneous DCE design was used. Such a DCE design, which included
several sub-designs, accommodated substantial respondent
heterogeneity in an efficient way [24], while keeping the burden
of a respondent to a manageable level. Third, our sample size of
1261 respondents was relative large compared to other health
related DCE studies [36]. Such a relative large sample size is bene-
ficial for reasons other than statistical precision (e.g. to facilitate
in-depth analysis) [31].
A potential weakness of the present study is that numbers and
rates were included in our DCE. This might have caused problems
with understanding the choice task. However, 97% of the respon-
dents reported that they did not find the DCE questions difficult.
We therefore believe that interpretation problems in our DCE did
not influence the results to a large extent. Second, the reported dis-
eases were based on respondent self-reports. This might deviate
from what a GP or formal medical registry would have reported,
Fig. 2a. One-way impact vaccination characteristics on vaccination uptake for base case.
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and hence might have had an influence on the results. Third,
although, the percentage of respondents (64%) who stated they
would opt for flu vaccination was in line with current Dutch prac-
tice (58%; CI 51%-65%), we cannot exclude that selection bias may
exist in our sample. Finally, the current results could gain credibil-
ity if it were possible to compare the stated preferences of elderly
people with their actual behaviour in influenza vaccination.
In summary, although vaccination characteristics proved to
influence influenza vaccination uptake, certain patient characteris-
tics (i.e., whether the patient had been vaccinated last year,
whether s/he had experienced vaccination side effects, and the
patient’s general attitude towards vaccination) had an even higher
impact on influenza vaccination uptake. Policy makers and general
practitioners can use these insights to improve their plans and
information regarding influenza vaccination for individuals aged
60 years or older. For instance, physicians should focus more on
patients who had experienced side effects due to vaccination in
the past, and policy makers should tailor the standard information
folder to patients who had been vaccinated last year and to patient
who had not.
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